A national database analysis for factors associated with thyroid cancer occurrence

Lee, Joon Hyop; Youn, Sora; Jung, Sua; Kim, Kwangsoo; Chai, Young Jun; Chung, Yoo Seung; Park, Won Seo; Lee, Kyu Eun; Yi, Ka Hee

doi:10.1038/s41598-020-74546-3

Cited by 6 publications

(3 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TSI can also stimulate angiogenesis, promote tumor development, and make tumors more aggressive (6). Previous studies have shown that the risk of DTC in patients with hyperthyroidism is 6.8 times higher than that in patients with normal thyroid function and that the longer the duration of hyperthyroidism is, the greater the risk of DTC and the worse the clinicopathological characteristics and prognosis (7)(8)(9)(10). In this study, the course of hyperthyroidism did not affect the efficacy of 131 I (P=0.441, U=834.00), but patients who received preoperative drug treatment for hyperthyroidism were more likely to achieve ER (P=0.005, χ 2 =10.62).…”

Section: Discussionmentioning

confidence: 99%

Efficacy evaluation and influencing factor analysis of postoperative 131I for the treatment of primary hyperthyroidism combined with differentiated thyroid cancer (DTC)—a retrospective cohort study

Zhao¹,

Han²,

Lu³

et al. 2023

Gland Surg

View full text Add to dashboard Cite

Background 131 I treatment is one of the important methods of comprehensive postoperative treatment for patients with hyperthyroidism complicated with differentiated thyroid cancer (DTC). Early identification of patients with poor treatment efficacy of 131 I is particularly important. Current studies mainly focus on the relationship between hyperthyroidism and the occurrence and development of DTC, and there are few studies on the factors affecting the curative effect. The purpose of this study was to find the influencing factors of efficacy evaluation and provide evidence for early identification of patients with poor efficacy in DTC combined with primary hyperthyroidism patients. Methods This was a retrospective analysis of DTC patients with primary hyperthyroidism who received 131 I treatment in our department from 2012 to 2021. Follow-up intervals were 3 months within 1 year, 6 months within 1 to 2 years, and annual follow-up thereafter, the median follow-up time was 12.0 (3.0, 24.0) months. Serological examination and imaging examination were used to evaluate the efficacy. Patients were classified into an excellent response (ER) group and a non-ER group based on treatment response more than 6 months after 131 I treatment. Univariate analysis and multivariate logistic regression analysis were performed on the basic clinical characteristics, pathological characteristics and curative effect of the patients, in order to find independent risk factors affecting the curative effect. Results Eighty-nine patients were mostly female (80.9%), the average age was 43.47±11.88 years old, and tumor size was 1.2 (0.75, 1.80) cm, 56 patients (62.9%) in the ER group. psTg [odds ratio (OR): 1.325; 95% confidence interval (CI): 1.135–1.547; P<0.001], maximum tumor diameter (OR: 2.428; 95% CI: 1.392–4.235; P=0.002) and pathology-confirmed combined HT (OR: 8.669; 95% CI: 1.877–40.038; P=0.006) were independent risk factors for predicting ER. Conclusions Our findings demonstrate that most hyperthyroidism combined with DTC patients could get favorable clinical outcomes from 131 I treatment. The tumor diameter, pathology-confirmed diagnosis of combined HT, and psTg level can be used to identify patients who can get ER by the effect of 131 I in hyperthyroidism combined with DTC at an early stage.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy evaluation and influencing factor analysis of postoperative 131I for the treatment of primary hyperthyroidism combined with differentiated thyroid cancer (DTC)—a retrospective cohort study

Zhao¹,

Han²,

Lu³

et al. 2023

Gland Surg

View full text Add to dashboard Cite

show abstract

“…The known risk factors for TC include female sex, obesity, smoking status, radioactive iodine exposure history, and family genetic history ( 86 – 88 ). However, these recognized causative factors do not fully explain the increasing incidence of TC.…”

Section: Discussionmentioning

confidence: 99%

Identification and Validation of Prognostic Related Hallmark ATP-Binding Cassette Transporters Associated With Immune Cell Infiltration Patterns in Thyroid Carcinoma

Wang

Sun

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

ATP-binding cassette (ABC) transporters are a large superfamily of membrane proteins that facilitate the translocation of heterogeneous substrates. Studies indicate that ABC transporters may play important roles in various carcinomas. However, the correlation between ABC transporters and immunomodulation in thyroid carcinoma (TC), as well as the prognoses for this disease, is poorly understood.TC data from The Cancer Genome Atlas (TCGA) database were used to identify prognostic hallmark ABC transporters associated with immune cell infiltration patterns via multiple bioinformatic analyses. Thereafter, quantitative real-time polymerase chain reaction (qRT-PCR) was performed to validate the expression of these selected hallmark ABC transporters in both TC and para-cancerous thyroid tissues. Of a total of 49 ABC transporters, five (ABCA8, ABCA12, ABCB6, ABCB8, and ABCC10) were identified as hallmark ABC transporters. All five were differentially expressed in TC and associated with the relapse-free survival rates of patients with TC. Immunoregulation by these five hallmark ABC transporters involved the modulation of various aspects of immune cell infiltration, such as hot or cold tumor subsets and the abundances of infiltrating immune cells, as well as specific immunomodulators and chemokines. Besides the diverse significantly correlated factors, the five hallmark ABC transporters and correlated genes were most highly enriched in plasma membrane, transporter activity, and transmembrane transport of small molecules. In addition, many chemicals, namely bisphenol A and vincristine, affected the expression of these five transporters. The qRT-PCR results of collected TC and para-cancerous thyroid tissues were consistent with those of TCGA. The findings in this study may reveal the role played by these five hallmark ABC transporters in regulating immune cell infiltration patterns in TC as well as the molecular mechanisms underlying their functions, leading to a better understanding of their potential prognostic and immunotherapeutic values.

show abstract

“…Incidences of TC are most common among younger adults [ 14 , 15 ]. Women are three times more likely to develop TC than men [ 10 , 16 ].…”

Section: Introductionmentioning

confidence: 99%

Novel Inhibitor-Based Therapies for Thyroid Cancer—An Update

Ratajczak

Gawel

Godlewska

2021

IJMS

View full text Add to dashboard Cite

Thyroid cancers (TCs) are the most common tumors of the endocrine system and a constant rise in the number of TC cases has been observed for the past few decades. TCs are one of the most frequent tumors in younger adults, especially in women, therefore early diagnosis and effective therapy are especially important. Ultrasonography examination followed by fine needle biopsy have become the gold standard for diagnosis of TCs, as these strategies allow for early-stage detection and aid accurate qualification for further procedures, including surgical treatment. Despite all the advancements in detection and treatment of TCs, constant mortality levels are still observed. Therefore, a novel generation line of targeted treatment strategies is being developed, including personalized therapies with kinase inhibitors. Recent molecular studies on TCs demonstrate that kinase inhibitor-based therapies might be considered as the most promising. In the past decade, new kinase inhibitors with different mechanisms of action have been reported and approved for clinical trials. This review presents an up-to-date picture of new approaches and challenges of inhibitor-based therapies in treatment of TCs, focusing on the latest findings reported over the past two years.

show abstract

A national database analysis for factors associated with thyroid cancer occurrence

Cited by 6 publications

References 30 publications

Efficacy evaluation and influencing factor analysis of postoperative 131I for the treatment of primary hyperthyroidism combined with differentiated thyroid cancer (DTC)—a retrospective cohort study

Efficacy evaluation and influencing factor analysis of postoperative 131I for the treatment of primary hyperthyroidism combined with differentiated thyroid cancer (DTC)—a retrospective cohort study

Identification and Validation of Prognostic Related Hallmark ATP-Binding Cassette Transporters Associated With Immune Cell Infiltration Patterns in Thyroid Carcinoma

Novel Inhibitor-Based Therapies for Thyroid Cancer—An Update

Contact Info

Product

Resources

About